Abstract 3827
Background
Cemiplimab (cemiplimab-rwlc in the US), a human monoclonal anti–PD-1 antibody, has shown substantial antitumour activity in pts with advanced malignancies and is FDA-approved for pts with advanced (metastatic or locally advanced) cutaneous squamous cell carcinoma (CSCC). We sought to compare weight-based and fixed dosing regimens of cemiplimab in pts with advanced malignancies.
Methods
This PK analysis included 505 pts with advanced tumours, including 135 pts with advanced CSCC, from phase I and phase II studies of cemiplimab (NCT02383212 and NCT02760498, respectively). Pts received either weight-based doses of cemiplimab (1, 3, 10 mg/kg every 2 weeks [Q2W] and 3 mg/kg every 3 weeks [Q3W]) or a fixed dose regimen (200 mg Q2W). This analysis pooled data from 10,935 PK samples including 2,023 samples from pts with advanced CSCC, to predict the Q3W fixed dose regiment with equivalent cemiplimab exposure as the recommended Phase II dose (3 mg/kg Q2W) using a 2compartment population PK (PopPK) model incorporating covariates that improved goodness-of-fit statistics. The selected fixed dose regimen was confirmed by PK data of the regimen in pts with advanced CSCC from the phase II trial.
Results
In the phase I study, dose-proportional kinetics were observed over the 1 to 10 mg/kg Q2W dose range. The 350 mg Q3W fixed dose regimen was selected based on PopPK model simulations as it provided similar cemiplimab exposure to 3 mg/kg Q2W at steady state (ss) over a 6-week (6wk) treatment period (e.g. mean AUC6wk, ss [coefficient of variation (CV)]: 3,800 [37.2%] and 3,710 [35.9%] mg*day/mL for 350 mg Q3W and 3 mg/kg Q2W, respectively). The observed exposures in patients with advanced CSCC in the phase II trial receiving 350 mg Q3W cemiplimab were comparable to the simulated exposures. In addition, the observed exposures at ss were similar between 3 mg/kg Q2W and 350 mg Q3W.
Conclusions
The results from PopPK simulations support the use of a 350 mg Q3W fixed dose regimen, with similar cemiplimab exposure to a weight-based 3 mg/kg Q2W regimen, in pts with advanced malignancies.
Clinical trial identification
NCT02383212 and NCT02760498.
Editorial acknowledgement
Bu Reinen of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc., and Sanofi.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
M.R. Migden: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Regeneron Pharmaceuticals, Inc.; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Honoraria (self), Travel / Accommodation / Expenses: Sun Pharma. A. Paccaly: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. K.P. Papadopoulos: Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution): Merck; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Merck KGaA; Research grant / Funding (institution): Mabspace Biosciences. F. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. J.D. Davis: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. R. Rippley: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. I. Lowy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. E. Stankevich: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. D. Rischin: Research grant / Funding (institution), Non-remunerated activity/ies: Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution), Non-remunerated activity/ies: GSK; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Research grant / Funding (institution), Non-remunerated activity/ies: Bristol-Myers Squibb; Research grant / Funding (institution): Roche.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract